A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Lufepirsen (Primary)
- Indications Wounds
- Focus Adverse reactions; Therapeutic Use
- Sponsors OcuNexus Therapeutics
- 08 Dec 2014 New trial record